NCT04521231 2026-04-16
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Phase 1/2 Recruiting
Clinical Trials
21 trialsNCT06308588 2026-04-14
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05327894 2026-04-13
Interfant-21
Princess Maxima Center for Pediatric Oncology
Phase 3 Recruiting
NCT05519579 2026-04-07
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Northside Hospital, Inc.
Phase 2 Recruiting
NCT04307576 2026-03-27
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Karolinska University Hospital
Phase 3 Recruiting
NCT06985485 2026-03-24
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT03263572 2026-02-25
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06533748 2026-02-12
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT06860269 2026-02-10
GRAALL-2024
Assistance Publique - Hôpitaux de Paris
Phase 2/3 Recruiting
NCT05848687 2026-01-13
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Phase 1/2 Recruiting
NCT06387121 2025-12-17
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT04260022 2025-11-05
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Ascentage Pharma Group Inc.
Phase 1 Recruiting
NCT07152041 2025-09-03
CAMS-Ph+ B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Recruiting
NCT06882057 2025-08-26
CCCG-LR-B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3 Recruiting
NCT07003737 2025-06-04
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
First Affiliated Hospital of Zhejiang University
Phase NA Recruiting
NCT03643276 2025-04-06
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
University Hospital Schleswig-Holstein
Phase 3 Recruiting
NCT06764238 2025-02-07
CCCG-I/HR-ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3 Recruiting
NCT06742515 2024-12-19
Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06250959 2024-04-04
BEAT-ALL-2024
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT06237192 2024-02-01
MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients
National Research Center for Hematology, Russia
Phase NA Recruiting
NCT06220487 2024-01-24
ABC
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting